DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20175470

Metastatic germ cell tumor with complete response-7 years follow up

Branislava Golub Jakovljevic, Dejan Đokanović, Snježana Miličević, Anđa Škobić, Dejan Ćazić, Vladimir Krivokuća

Abstract


Cancer of the testis is a relatively uncommon disease, accounting for approximately 1-1.5% of all cancers in males.  5% of the malignant germ cell tumors are made of extragonadal origin. Germ cell tumors occur in men younger, usually between 20 and 35 years old. We report a case of a patient with metastatic extragonadal germ cell tumor with multiple sites of metastases, and very high initial values of tumor marker human chorionic gonadotrophin (HCG)- 1351308. At the time of diagnosis, the patient was in a very poor general condition. After the applied chemotherapy, there was a complete response and 7 years later the patient is without any symptoms of disease.


Keywords


Complete response, Germ cell tumor, Metastatic disease

Full Text:

PDF

References


Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmol HJ, Bokemeyer C, et al. Testicular Seminoma and Non-Seminoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2013;24(Suppl 6):vi125-vi132.

Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Møller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Inter J Cancer. 2006;118(12):3099-111.

Schmoll HJ, Jordan K, Huddart R, Pes ML, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl_5):v140-6.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer J Clinic. 2016;66(1):7-30.

Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Inter Medic. 1977;87(3):293-8.

Huddart R, Kataja V. ESMO Guidelines Working Group. Mixed or non- seminomatous germ-cell tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:49-51.

Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008;299:672-684.

Schmoll HJ. Extragonadal germ cell tumors. Annals of Oncology. 2002;13(suppl_4):265-72.

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Euro Urol. 2008;53(3):478-96.

Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ. Treatment of brain metastases in patients with testicular cancer. J Clinic Oncol. 1997;15(4):1449-54.

Hartmann JT, Fossa SD, Nichols CR, Droz JP, Horwich A, Gerl A, et al. Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Nation Can Insti. 2001;93(22):1733-8.

Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, et al. The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer. 2000;88(11):2629-35.

Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, et al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Nation Can Insti. 2000;92(1):54-61.